Your genes could hold the key to better depression treatment

NCT ID NCT07738497

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing whether using a genetic test to choose antidepressants leads to better outcomes for people with major depressive disorder. Half of the 220 participants will have their treatment guided by a cheek swab that analyzes genes affecting drug metabolism, while the other half will receive standard care. The study will compare response rates, side effects, and how often medication adjustments are needed over 12 weeks, with the goal of moving toward more personalized depression care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pharmacogenomic testing (genetic test from a cheek swab) to guide antidepressant selection
What this could lead to
If successful, this could make depression treatment more personalized, helping doctors choose the right antidepressant based on a patient's genes, potentially improving response rates and reducing side effects.
What could go wrong
The trial is relatively small and early, and genetic testing may not always predict real-world drug response. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Inflammation major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.